Overview

Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor

Status:
Recruiting
Trial end date:
2025-10-31
Target enrollment:
Participant gender:
Summary
A phase II, open-label, multicenter study to evaluate the efficacy and safety of oral TT-00420 (Tinengotinib) tablets in subjects with cholangiocarcinoma who failed or relapsed to prior treatment of chemotherapy and FGFR Inhibitor.
Phase:
Phase 2
Details
Lead Sponsor:
TransThera Sciences (Nanjing), Inc.